Mood symptoms and chronic fatigue syndrome due to relapsing remitting multiple sclerosis are associated with immune activation and aberrations in the erythron DOI Creative Commons
Abbas F. Almulla,

Al-Karrar Kais Abdul Jaleel,

Ali Abbas Abo Algon

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2022, Volume and Issue: unknown

Published: Dec. 30, 2022

Abstract Background Multiple sclerosis (MS) is a chronic autoimmune and neuroinflammatory disease of the central nervous system characterized by peripheral activation immune-inflammatory pathways which culminate in neurotoxicity causing demyelination neurons. Nonetheless, pathophysiology relapsing-remitting MS (RRMS)-related fatigue, depression, anxiety, cognitive impairments, autonomic disturbances not well understood. Objectives The current study aims to delineate whether remitted phase RRMS accompanied activated if latter, coupled with erythron variables, explain fatigue mood symptoms due RRMS. Material Methods We recruited 63 patients, 55 8 secondary progressive MS, 30 healthy controls assessed variables used bio-plex assay measure 27 serum cytokines. Results A significant part patients (46%) displayed response (IRS) compensatory immune (CIRS) systems, T helper (Th)1 Th-17 cytokine profiles. Remitted showed increased physiosomatic, autonomic, insomnia scores, could partly be explained M1 macrophage, Th1, Th-17, growth factor, CIRS activation, as aberrations including lowered hematocrit hemoglobin levels. Conclusions Around 50% show association chronic-fatigue-like symptoms. IRS are new drug targets treat affective MS.

Language: Английский

Changes in Inflammatory Biomarkers in Patients with Schizophrenia: A 3-Year Retrospective Study DOI Creative Commons
Xiaoyu Zhu, Ran Li,

Yu Zhu

et al.

Neuropsychiatric Disease and Treatment, Journal Year: 2023, Volume and Issue: Volume 19, P. 1597 - 1604

Published: July 1, 2023

Accumulating evidence suggested that immune system activation might be involved in the pathophysiology of schizophrenia. The neutrophil/lymphocyte ratio (NLR), monocyte/lymphocyte (MLR), platelet/lymphocyte (PLR) and systemic immune-inflammation index (SII) can measure inflammation. This study aimed to investigate inflammatory state patients with schizophrenia by using these indicators.

Language: Английский

Citations

11

IL-17A, IL-23R, FCGR3A are associated with neuropsychiatric systemic lupus erythematosus susceptibility in pediatric patients with lupus nephritis DOI
Chen Ye, Lizhi Chen, Lu Zhang

et al.

Cytokine, Journal Year: 2025, Volume and Issue: 188, P. 156874 - 156874

Published: Feb. 3, 2025

Language: Английский

Citations

0

In Schizophrenia, the Effects of the IL-6/IL-23/Th17 Axis on Health-Related Quality of Life and Disabilities Are Partly Mediated by Generalized Cognitive Decline and the Symptomatome DOI Open Access

Ali Fattah Al-Musawi,

Hussein Kadhem Al‐Hakeim,

Zahraa Abdulrazaq Al-Khfaji

et al.

International Journal of Environmental Research and Public Health, Journal Year: 2022, Volume and Issue: 19(22), P. 15281 - 15281

Published: Nov. 18, 2022

Schizophrenia patients show increased disabilities and lower quality of life (DisQoL). Nevertheless, there are no data on whether the activation interleukin (IL)-6, IL-23, T helper (Th)-17 axis, magnesium calcium levels impact DisQoL scores. This study recruited 90 with schizophrenia (including 40 deficit schizophrenia) healthy controls assessed World Health Association QoL instrument-Abbreviated version Sheehan Disability scale, Brief Assessment Cognition in (BACS), IL-6, IL-17, IL-21, IL-22, tumor necrosis factor (TNF)-α, calcium. Regression analyses showed that a large part first extracted from physical, psychological, social environmental HR-QoL interference school/work, life, home responsibilities was predicted by generalized cognitive deterioration (G-CoDe) index (a latent vector BACs scores), various symptom domains (“symptomatome”), whereas biomarkers had effects. Partial Least Squares analysis IL6IL23Th17 axis magnesium/calcium highly significant total (indirect + direct) effects HR-QoL/disabilities, which were mediated G-CoDe symptomatome negative positive symptoms). The explained 63.1% variance behavioral-cognitive-psycho-social (BCPS) worsening single trait G-CoDe, symptomatome, disability data. In summary, BCPS is partly caused neuroimmunotoxic subjects lowered antioxidant defenses (magnesium calcium), thereby probably damaging neuronal circuits may underpin schizophrenia.

Language: Английский

Citations

13

Mood Symptoms and Chronic Fatigue Syndrome Due to Relapsing-Remitting Multiple Sclerosis Are Associated with Immune Activation and Aberrations in the Erythron DOI Creative Commons
Abbas F. Almulla,

Al-Karrar Kais Abdul Jaleel,

Ali Abbas Abo Algon

et al.

Brain Sciences, Journal Year: 2023, Volume and Issue: 13(7), P. 1073 - 1073

Published: July 14, 2023

Multiple sclerosis (MS) is a chronic autoimmune and neuroinflammatory disease of the central nervous system characterized by peripheral activation immune-inflammatory pathways which culminate in neurotoxicity causing demyelination neurons. Nonetheless, pathophysiology relapsing-remitting MS (RRMS)-related fatigue, depression, anxiety, cognitive impairments, autonomic disturbances not well understood.The current study aims to delineate whether remitted phase RRMS accompanied activated if latter, coupled with erythron variables, explain fatigue mood symptoms due RRMS.We recruited 63 patients, 55 8 secondary progressive MS, 30 healthy controls assessed used bio-plex assay measure 27 serum cytokines.A significant proportion patients (46%) displayed response (IRS) compensatory immune (CIRS) systems, T helper (Th)1 Th17 cytokine profiles. Remitted showed increased physiosomatic, autonomic, insomnia scores, could partly be explained M1 macrophage, Th1, Th-17, growth factor, CIRS activation, as aberrations including lowered hematocrit hemoglobin levels.Around 50% show association chronic-fatigue-like symptoms. IRS are new drug targets treat affective MS.

Language: Английский

Citations

8

Pilot study indicates that a gluten-free diet lowers oxidative stress for gluten-sensitive persons with schizophrenia DOI
Eunkyoung Kim,

Sidney Redwood,

Fang Liu

et al.

Schizophrenia Research, Journal Year: 2024, Volume and Issue: 269, P. 71 - 78

Published: May 14, 2024

Language: Английский

Citations

2

Elevated serum IL-17 A and CCL20 levels as potential biomarkers in major psychotic disorders: a case-control study DOI Creative Commons

Parisa Ghasemi Noghabi,

Najmeh Shahini, Zanireh Salimi

et al.

BMC Psychiatry, Journal Year: 2024, Volume and Issue: 24(1)

Published: Oct. 11, 2024

Major psychotic disorders (MPD), including schizophrenia (SCZ) and schizoaffective disorder (SAD), are severe neuropsychiatric conditions with unclear causes. Understanding their pathophysiology is essential for better diagnosis, treatment, prognosis. Recent research highlights the role of inflammation immune system, particularly Interleukin 17 (IL-17) family, in these disorders. Elevated IL-17 levels have been found MPD, human A antibodies available. Changes chemokine levels, such as CCL20, also noted SCZ. This study investigates relationship between serum CCL20 MPD patients clinical characteristics. We conducted a case-control at Ibn Sina Psychiatric Hospital (Mashhad, Iran) 2023. The involved 101 participants, which 71 were 30 healthy controls (HC). Positive Negative Symptom Scale (PANSS) was utilized to assess symptoms patients. Serum measured using Enzyme-Linked Immunosorbent Assay (ELISA) kits. gathered data on lipid profiles Fasting Blood Glucose (FBS). mean age 41.04 ± 9.93 years. median significantly elevated compared HC (5.8 (4.1–15.3) pg/mL 4.2 (3–5) pg/mL, respectively; p < 0.001). Furthermore, showed positive correlation severity MPD. had higher FBS, cholesterol, Low-Density Lipoprotein (LDL) lower High-Density (HDL) HC. No significant PANSS components blood IL17 CCL20. current revealed that than those control group. Metabolic factors HDL, LDL differences In conclusion, findings suggest two inflammatory could serve potential therapeutic targets prognostic biomarkers schizophrenia.

Language: Английский

Citations

2

Chronic fatigue syndrome, depression, and anxiety symptoms due to relapsing-remitting multiple sclerosis are associated with reactivation of Epstein-Barr virus and Human Herpesvirus 6. DOI Creative Commons
Michaël Maes, Abbas F. Almulla, Elroy Vojdani

et al.

medRxiv (Cold Spring Harbor Laboratory), Journal Year: 2024, Volume and Issue: unknown

Published: Oct. 14, 2024

Relapsing-remitting multiple sclerosis (RRMS) is defined by elevated IgG/IgA/IgM responses targeting Epstein-Barr Virus (EBV) nuclear antigen 1 (EBNA) and deoxyuridine-triphosphatases (dUTPases) of Human herpsesvirus-6 (HHV-6) EBV. These suggest that the viruses are being replicated reactivated. An increased prevalence chronic fatigue syndrome, depression, anxiety associated with signs immune activation in RRMS. Nevertheless, there a lack data regarding association between viral reactivation neuropsychiatric symptoms This study investigated to EBNA, EBV HHV-6-dUTPases, 58 remitted RRMS patients 63 normal controls. The McDonald criteria were employed establish diagnosis MS. Expanded Disability Status Scale (EDSS) Multiple Sclerosis Severity Score evaluate disabilities caused We evaluated scores Hamilton Depression (HAMD) Anxiety (HAMA) Rating Scales, Fibro-Fatigue (FF) scale. One latent construct was extracted from EDSS, MSSS, FF, HAMD, HAMA scores. discovered combined effects IgG IgM-HHV-6-dUTPAses accounted for 63.7% variance this construct. Furthermore, total HAMA, HAMD substantially IgM-HHV-6-dUTPAses, accounting approximately 38.7% 51.0% variance. three rating scale also significantly correlated IgA reactivity directed both dUTPases EBNA. replication HHV-6 contributes as well depression due

Language: Английский

Citations

2

Increased Lipid Peroxidation and Lowered Antioxidant Defenses Predict Methamphetamine Induced Psychosis DOI Creative Commons
Hussein Kadhem Al‐Hakeim,

Mazin Fadhil Altufaili,

Abbas F. Almulla

et al.

Cells, Journal Year: 2022, Volume and Issue: 11(22), P. 3694 - 3694

Published: Nov. 21, 2022

Background: a significant percentage of methamphetamine (MA) dependent patients develop psychosis. The associations between oxidative pathways and MA-induced psychosis (MIP) are not well delineated. Objective: the aim this study is to delineate whether acute MA intoxication in accompanied by increased nitro-oxidative stress latter associated with MIP. Method: we recruited 30 healthy younger males 60 acutely intoxicated dependence assessed severity use psychotic symptoms during intoxication, serum toxicity (OSTOX) biomarkers including oxidized high (oxHDL) low (oxLDL)-density lipoprotein, myeloperoxidase (MPO), malondialdehyde (MDA), nitric oxide (NO), antioxidant defenses (ANTIOX) HDL-cholesterol, zinc, glutathione peroxidase (GPx), total capacity (TAC), catalase-1. Results: large part (50%, n = 30) could be allocated cluster characterized ratings delusions, suspiciousness, conceptual disorganization difficulties abstract thinking an OSTOX/ANTIOX ratio. Partial Least Squares analysis showed that 29.9% variance MIP (a first factor extracted from psychosis, hostility, excitation, mannerism, formal thought disorder scores) was explained HDL, TAC zinc (all inversely) oxLDL (positively). dosing together 44.7% Conclusions: lowered defenses, both which increase risk intoxication. atherogenicity due HDL oxHDL.

Language: Английский

Citations

11

MONOCLONAL ANTIBODY THERAPY IN AUTOANTIBODY-ASSOCIATED PSYCHOTIC DISORDERS AND SCHIZOPHRENIA: NARRATIVE REVIEW OF PAST AND CURRENT CLINICAL TRIALS DOI Open Access

Niels Hansen,

Berend Malchow

Psychiatria Danubina, Journal Year: 2023, Volume and Issue: 35(1), P. 8 - 15

Published: April 13, 2023

Neural cell-surface autoantibody-associated psychiatric disease and a subgroup of psychotic disorders are probably caused by an immune dysregulation such as B-cell related autoantibody production.In this review we describe past current randomized placebo-controlled trials investigating monoclonal antibodies therapy for disorders, aiming to delineate the landscape in well perspectives future trials.Rituximab ocrelizumab now being tested clinical trials, whereas initial results on tocilizumab controversial, they demonstrated cognitive-function benefit open label study schizophrenic patients -results that were not replicated trial.Adalinumab TNFalpha blockage was effective treating positive negative symptoms schizophrenia.These findings demonstrate antibody is potentially promising option treat subgroups schizophrenia patients, but it should be investigated more placebo-controlled, double-blind with large cohorts.

Language: Английский

Citations

6

Role of different omics data in the diagnosis of schizophrenia disorder: A machine learning study DOI

Aarthy Varathan,

Suntharalingam Senthooran,

Pratheeba Jeyananthan

et al.

Schizophrenia Research, Journal Year: 2024, Volume and Issue: 271, P. 38 - 46

Published: July 14, 2024

Language: Английский

Citations

2